The Menin inhibitor Revumenib was studied in the phase 1 AUGMENT-101 trial in patients with KMT2A rearranged and NPM1m R/R AML patients as well as KMT2Ar ALL [71•]. The gene discussed is MEN1; the disease is acute myeloid leukemia.